Here is another great quote from GRCV “"Shareholders can be assured that as a management team, we are committed to Grand Capital Ventures becoming even more of an industry leader in our space while demonstrating our ability to continue to grow revenues and profits each year."”

Check this out, guys. The CEO went on to say in the VPOR news: ““The recent passage of the farm bill has opened the door wide open for innovators and entrepreneurs to disrupt the old CBD industry, and our new business model is a reflection of the coming change,”

Impressive management team at CLCI: “We leveraged a global network of industry professionals comprised of many disciplines and with a common vision.”

Nice GRCV quote here: “"It's exciting for us to now be part of a public company and to be charged with the stewardship of further building the enterprise for the benefits of our team and shareholders alike,"”

Nice CEO quote here from VPOR: “The recent passage of the farm bill has opened the door wide open for innovators and entrepreneurs to disrupt the old CBD industry, and our new business model is a reflection of the coming change,”

I agree. Very promising opportunities here for CLCI

Me too. The focus is on GRCV lately

Looks good, Let's Roll. Eyes on VPOR today

This technology could be huge! CLCI ’s tech allows merchants to accept crypto payments.

Nice.. Avitan and Biton both formed part of the leadership team that built YUKA into a profitable B2B partner known for delivering brand exposure and e-commerce expertise for their global clients. GRCV

The signing of the farm bill is great for CBD stocks like VPOR https://www.washingtonpost.com/business/2018/12/11/congresss-billion-farm-bill-is-out-heres-whats-it/?noredirect=on&utm_term=.215ecca05910

Nice. I saw CLCI has a clicwallet too. Not only clicpay.

I read that GRCV’s recent change of control comes on the heels of the Company's acquisition of Miami-based, e-commerce company Yuka Clothing, Inc. ("YUKA").

Nice statistic here from the VPOR news: A recent surveys suggest that close to 7 percent of Americans currently use the hemp-derived compound CBD

CLCI’s latest cryptocurrency app that helps retailers process blockchain payments is expected to be released later this year

Did you see that GRCV recently appointed a new ceo? https://finance.yahoo.com/news/grand-capital-ventures-inc-grcv-133000549.html

Check this out, guys. The $40,000 purchase order is a result of VPOR ‘s newly adopted business model that concentrates on providing premium, bulk CBD isolate to companies selling into the rapidly expanding CBD market.

Awesome looking CLCI website here: https://www.clictechnology.com/

Very nice.. GRCV is providing branding and business services to the over $2.86 trillion e-commerce market.

Yeah, VPOR is smart to restructure their business and focus now on CBD.

Here’s how it works. On CLCI ‘s website they explain it better. “When your customers pay in cryptocurrency, you receive payment via ACH directly to your bank account.”

I read that GRCV is doing some corporate restructuring!

Nice. $VPOR ‘s first bulk order of CBD isolate was mentioned in the April 3rd news.

Big news out from CLCI yesterday! CLIC Technology Begins Development and Testing of CLICPay Checkout In-Store Application https://finance.yahoo.com/news/clic-technology-begins-development-testing-133000588.html

Looks like GRCV just relocated their corporate office. Moving to bigger things.

Hey everyone. A very interesting CBD stock in $VPOR here

That's what the action appears to be. A lot of accumulating around the 4 mark lately

looks like everyone is trying to load here down cheap

Large volume day. Hopefully we see a bounce on QBIO

big volume day here today

The QBIO product roadmap provides key insight into the business model from which investors can extrapolate a future, tangible value range.

Diagnostic

Upon clearance or approval of the diagnostic kit, Q BioMed would charge a to-be-determined fee to the ophthalmologist for each assay and analysis. Since glaucoma is a lifelong disease, these swift tests will have to be performed on a routine basis on patients to preserve visual acuity and measure progression, it renders the kit as a recurring (and compounding) revenue stream for the physician and the Company. Considering 70 million are afflicted today, and millions more could be tested for measurement and progression at earlier intervals, it is reasonable to expect that one in three patients could regularly undergo this test, generating considerable revenue.

The QBIO product roadmap provides key insight into the business model from which investors can extrapolate a future, tangible value range.

Diagnostic

Upon clearance or approval of the diagnostic kit, Q BioMed would charge a to-be-determined fee to the ophthalmologist for each assay and analysis. Since glaucoma is a lifelong disease, these swift tests will have to be performed on a routine basis on patients to preserve visual acuity and measure progression, it renders the kit as a recurring (and compounding) revenue stream for the physician and the Company. Considering 70 million are afflicted today, and millions more could be tested for measurement and progression at earlier intervals, it is reasonable to expect that one in three patients could regularly undergo this test, generating considerable revenue.

Things are really coming together for QBIO

Very nice QBIO news out today. The Biointerfaces Institute will work with Mannin Research to create, assess, and apply DNA aptamers for detecting GDF15 in aqueous humor of patients with different severities of glaucoma. The intent is to create multiple prototype assays for the detection of GDF15 which will be suitable for point-of-care testing. Thus, the prototype kits are to be validated in a clinical setting. This personalized medicine approach illustrates the underlying innovation of the platform technology whose key function is to improve disease progression measurement and patient treatment outcomes.

Very nice QBIO news out today. The Biointerfaces Institute will work with Mannin Research to create, assess, and apply DNA aptamers for detecting GDF15 in aqueous humor of patients with different severities of glaucoma. The intent is to create multiple prototype assays for the detection of GDF15 which will be suitable for point-of-care testing. Thus, the prototype kits are to be validated in a clinical setting. This personalized medicine approach illustrates the underlying innovation of the platform technology whose key function is to improve disease progression measurement and patient treatment outcomes.

Yep. get the weak handed out! more to come

This is great news. QBIO is coming alive this spring

In the press release, QBIO details the next steps: The Next Steps

This enabling technology will act as a companion diagnostic to the MAN-01 small molecule therapeutic with a novel mechanism of action for the treatment of Primary Open-Angle Glaucoma. The aim is to develop a simple integrated diagnostic test that can be performed at a physician's office with no external, expensive equipment.

In the press release, QBIO details the next steps: The Next Steps

This enabling technology will act as a companion diagnostic to the MAN-01 small molecule therapeutic with a novel mechanism of action for the treatment of Primary Open-Angle Glaucoma. The aim is to develop a simple integrated diagnostic test that can be performed at a physician's office with no external, expensive equipment.

DIRV is winning new contracts, left and right!